Rigel surges as FDA waives panel; Troubled Endocyte looks for comeback following $12M licensing deal; Seattle Genetics scores a ‘breakthrough’
→ Shares of Rigel Therapeutics $RIGL bounded up about 20% this morning after the biotech reported that the FDA has no plans to call an expert panel together to review fostamatinib in patients with chronic or persistent immune thrombocytopenia. The FDA also has indicated that it expects to hit its April 17, 2018, PDUFA deadline for a decision. There are no guarantees, of course, but that’s all generally considered positive.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.